Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Clinical setback lays bare Vertex’s weakness
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
